Cerebras Upsizes IPO to $4.8 Billion as AI-Chip Listing Demand Surges

What Happened

AI-chip maker Cerebras Systems has lifted the size of its planned initial public offering by roughly one-third, targeting proceeds of up to $4.8 billion, Bloomberg’s Caroline Hyde and Ed Ludlow reported on Monday. The upsizing follows the amended S-1 Cerebras filed with the U.S. Securities and Exchange Commission on May 4, 2026, which marketed 28 million Class A shares at a price range of $115–$125. The implied fully diluted market value at the midpoint sits near $26.6 billion. Underwriters Morgan Stanley, Citigroup, Barclays and UBS are reportedly fielding around $10 billion in indications of interest, according to people familiar with the order book.

Why It Matters

If Cerebras prices at or above the top of the range, the deal will be one of the largest U.S. technology IPOs of 2026 and a clear marker for institutional appetite for AI-infrastructure equity outside the Nvidia franchise. The listing follows CoreWeave’s March 2025 IPO at NASDAQ:CRWV — the first investment-grade-rated GPU-backed financing in public markets — and lands the same quarter Lambda Labs is reportedly preparing pre-IPO convertible notes. The CBRS listing therefore tests whether public-market valuations for AI-chip and compute companies can sustain the multiples implied by recent private rounds.

For Cerebras specifically, the IPO is a public-market step-up from the company’s $23 billion Series H valuation that closed in February 2026. The $26.6 billion midpoint values the company at roughly 16 times forward revenue, per analyst estimates.

Technical Details

Cerebras builds wafer-scale chips, with its third-generation WSE-3 wafer-scale engine integrating 4 trillion transistors and 900,000 AI-optimised cores on a single chip the size of a dinner plate. The company has positioned its hardware as an alternative to Nvidia’s GPU clusters for large-language-model training and inference, claiming order-of-magnitude reductions in inter-chip communication latency for certain workloads. Cerebras has commercial relationships with OpenAI as a partner for select inference workloads, as well as with G42 and Mayo Clinic.

The amended S-1 lists Morgan Stanley, Citigroup, Barclays, and UBS as joint book-running managers. The CBRS ticker will trade on the Nasdaq Global Select Market. The offering structure includes a customary 15 percent overallotment option, which if fully exercised could lift gross proceeds further.

Who’s Affected

Existing Cerebras shareholders — including Foundation Capital, Benchmark, Eclipse Ventures, G42, and Altimeter — see an exit pathway at a step-up from the private mark. Public-market investors gain a second pure-play AI-infrastructure ticker after CoreWeave. Nvidia faces a marginal additional competitor in the AI-training and inference market, though Cerebras’s go-to-market remains focused on hyperscale and sovereign deployments rather than enterprise GPU clouds. The IPO’s reception will also signal to companies like Groq and SambaNova whether the public-market window for AI-chip listings is open.

What’s Next

Pricing is expected later this week. If filled at the top of the range, Cerebras would join Palantir, CoreWeave, and Anthropic-adjacent listed entities as one of the largest pure-AI public companies by market cap at IPO. Cerebras did not publicly forecast use-of-proceeds beyond general corporate purposes, working capital, and potential acquisitions. The company has previously stated that capacity expansion at its Texas manufacturing partner and additional data-centre buildouts for inference workloads are the largest near-term capital priorities.